Efficacy and safety evaluation of lorecl
β
T Rentmeester; J Hulsman
π
Article
π
1991
π
Elsevier Science
π
English
β 381 KB
Thirteen drug-resistant epilepsy patients received loreclezole as add-on therapy. The trial lasted 6 months. Loreclezole was dosed to reach a target plasma concentration between 1 and 3 mg/l. The seizure frequency in the total group decreased by 23%. A reduction of 50% or more was observed in four p